Drugs / MM36
last change Jun 2017 re-read 3 minutes ago

MM36

Developed for
atopic eczema
Investigated by
Medimetriks Pharmaceuticals, Inc

Trials 1

20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02945657 Oct 2016 → Jun 2017 atopic eczema Medimetriks Pharmaceuticals, Inc Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MM36 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02945657 ↗
Route Topical “topical MM36 (OPA-15406) ointment” NCT02945657 ↗